1 active not recruiting, 1 completed, 1 suspended, 1 withdrawn. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Suspended 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Thomas Martin, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma Leukapheresis, Cyclophosphamide, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Suspended | Thomas Martin, MD | 30 | 2026-02-28 | 2026-06-11 |
| Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma Manufactured Anti-BCMA CAR-T cells, Fludarabine, Cyclophosphamide - Refractory Multiple Myeloma, Relapsed Multiple Myeloma | Phase 1 | Active not recruiting | Thomas Martin, MD | 5 | 2021-10-18 | 2026-02-20 |
| Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma Rapid Infusion Isatuximab - Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Withdrawn | Thomas Martin, MD | 2021-05-28 | 2022-07-07 | |
| Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma Isatuximab, Carfilzomib, Dexamethasone - Multiple Myeloma | Phase 1 | Completed | Thomas Martin, MD | 83 | 2015-01-21 | 2026-06-11 |
Multiple Myeloma (4) · Recurrence (1)
Cyclophosphamide (2) · fludarabine (2) · isatuximab (2) · Biopsy (1) · Calcium Dobesilate (1) · Dexamethasone (1) · Immunotherapy, Adoptive (1) · Leukapheresis (1) · Magnetic Resonance Spectroscopy (1) · Phantoms, Imaging (1) · Quality of Life (1) · Specimen Handling (1) · Surveys and Questionnaires (1) · carfilzomib (1) · dexamethasone 21-phosphate (1)
United States (3) · Canada (1)